BioSpace News Archive

Advicenne (Paris:ADVIC), a specialist pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announces today that the company strengthens its scientific relationship with the European Society for Paediatric Nephrology (ESPN) during the 51st Annual Meeting which is being held October 3-8, 2018, in Antalya, Turkey.

Technavio analysts forecast the global medical crutches market to grow at a CAGR of over 5% during the forecast period, according to their latest market research report.

ProSource360 announced today it is joining Cerner, a global leader in health care technology, and other industry leaders and innovators to help make seamless care available to the nation’s veterans.

Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) today announced that Health Canada has granted market authorization of RADICAVA™ (edaravone) as an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS), a rapidly progressive, neurodegenerative disease.1,2

Richmond Vascular Center, Central Virginia’s state-of-the-art treatment center for Radiology Associates of Richmond and Surgical Associates of Richmond, is the first US site to offer the Ellipsys® Vascular Access System, a game-changing innovation for patients with End-Stage Renal Disease (ESRD).

An inventor from Raytown, Mo., wanted to fulfill the need for a customizable modular heat and cold therapy device.

Griffin-American Healthcare REIT III, Inc. announced today that its board of directors has approved an updated estimated per share net asset value (“NAV”) of its common stock of $9.37 calculated as of June 30, 2018.

ivWatch, the only provider of continuous monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, entered into a long-term development and commercialization agreement with ICU Medical, a worldwide leader in the development, manufacture and sale of innovative medical devices used in infusion therapy and critical care applications.

RealSelf, the world’s leading online marketplace to learn about cosmetic treatments and connect with doctors and other clinicians, today launched Beyond Scars: Healing Bodies. Restoring Lives,

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that its lead NR2F6 small molecule agonist, RG-NAH005, is now ready for testing in animal models of inflammatory bowel disease (IBD)